Table 1.
Characteristics of patients included in the study using cases (graft failure) versus controls (engraftment)
| Variable | Graft failure |
Engraftment |
||
|---|---|---|---|---|
| No. evaluated | No. (%) | No. evaluated | No. (%) | |
| No. of patients | 37 | 78 | ||
| No. of centers | 22 | 33 | ||
| Median age, y (range) | 37 | 35 (7-53) | 78 | 36 (5-54) |
| Age at transplantation, y | 37 | 78 | ||
| Less than 10 | 1 (3) | 1 (1) | ||
| 11-20 | 4 (11) | 9 (12) | ||
| 21-30 | 9 (24) | 18 (23) | ||
| 31-40 | 11 (30) | 22 (28) | ||
| 41-50 | 10 (27) | 24 (31) | ||
| More than 50 | 2 (5) | 4 (5) | ||
| Male sex | 37 | 17 (46) | 78 | 45 (58) |
| Karnofsky before treatment > 90% | 36 | 26 (72) | 76 | 51 (67) |
| Overall HLA matching | 37 | 78 | ||
| 12/12 | 2 (5) | 4 (5) | ||
| 11/12 | 4 (11) | 11 (14) | ||
| 10/12 | 6 (16) | 26 (33) | ||
| 9/12 | 11 (30) | 18 (23) | ||
| 8/12 | 7 (19) | 8 (10) | ||
| 7/12 | 5 (14) | 6 (8) | ||
| 6/12 | 2 (5) | 5 (7) | ||
| HLA mismatch distribution | ||||
| HLA-A | 13 (35) | 25 (32) | ||
| HLA-B | 13 (35) | 25 (32) | ||
| HLA-C | 22 (59) | 38 (49) | ||
| HLA-DRB1 | 3 (8) | 8 (10) | ||
| HLA-DQB1 | 10 (27) | 13 (17) | ||
| HLA-DPB1 | 33 (89) | 63 (81) | ||
| Disease at transplantation | 37 | 78 | ||
| AML | 12 (32) | 26 (33) | ||
| ALL | 2 (5) | 5 (6) | ||
| CML | 20 (54) | 41 (53) | ||
| MDS | 3 (8) | 6 (8) | ||
| Disease status at transplantation | 37 | 78 | ||
| Early | 13 (35) | 28 (36) | ||
| Intermediate | 14 (38) | 30 (38) | ||
| Advanced | 9 (24) | 19 (24) | ||
| Other | 1 (3) | 1 (1) | ||
| Stem cell source | 37 | 78 | ||
| Bone marrow | 36 (97) | 76 (97) | ||
| PBSC | 1 (3) | 2 (3) | ||
| Conditioning regimen | 37 | 78 | ||
| Myeloablative | 36 (97) | 76 (97) | ||
| Reduced intensity | 1 (3) | 2 (3) | ||
| GVHD prophylaxis | 37 | 78 | ||
| CsA or FK506 + MTX ± other | 36 (97) | 73 (93) | ||
| CsA or FK506 ± other (no MTX) | 0 | 2 (3) | ||
| MTX ± other | 1 (3) | 2 (3) | ||
| Other | 0 | 1 (1) | ||
| Donor/recipient sex match | 37 | 78 | ||
| Male/male | 5 (14) | 31 (40) | ||
| Male/female | 12 (32) | 20 (26) | ||
| Female/male | 12 (32) | 14 (18) | ||
| Female/female | 8 (22) | 13 (17) | ||
| Donor/recipient CMV match | 37 | 78 | ||
| Negative/negative | 4 (11) | 29 (37) | ||
| Negative/positive | 15 (41) | 24 (31) | ||
| Positive/negative | 10 (27) | 7 (9) | ||
| Positive/positive | 5 (14) | 17 (22) | ||
| Unknown | 3 (8) | 1 (1) | ||
| Donor median age, y (range) | 37 | 36 (21-52) | 78 | 35 (18-54) |
| Donor age, y | 37 | 78 | ||
| 18-29 | 11 (30) | 21 (27) | ||
| 30-39 | 12 (32) | 35 (45) | ||
| 40-49 | 13 (35) | 14 (18) | ||
| 50 and older | 1 (3) | 8 (10) | ||
| Year of transplantation | 37 | 78 | ||
| 1990 | 0 | 1 (1) | ||
| 1991 | 0 | 0 | ||
| 1992 | 1 (3) | 6 (8) | ||
| 1993 | 3 (8) | 7 (9) | ||
| 1994 | 3 (8) | 7 (9) | ||
| 1995 | 6 (16) | 5 (6) | ||
| 1996 | 5 (14) | 10 (13) | ||
| 1997 | 4 (11) | 6 (8) | ||
| 1998 | 2 (5) | 8 (10) | ||
| 1999 | 5 (14) | 8 (10) | ||
| 2000 | 3 (8) | 11 (14) | ||
| 2001 | 5 (14) | 7 (9) | ||
| 2002 | 0 | 2 (3) | ||
| Median follow-up of survivors, mo | 3 | 72 (70-74) | 21 | 65 (38-158) |
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; and MTX, methotrexate.